Product news from the 08/15/06 News Brief
The FDA has approved Novartis’ Exelon (rivastigmine tartrate) for the treatment of mild to moderate Parkinson's disease dementia, making it ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.